Common Variable Immunodeficiency, Vascular Diseases
Conditions
Keywords
Common variable immunodeficiency, Porto-sinusoidal vascular disease, Gut microbiota
Brief summary
This aim of this study is the evaluation of the gut microbiota imbalance occurrence and its characterization in patients with common variable immunodeficiency associated to an enteropathy with or without porto-sinusoidal vascular disease.
Detailed description
Common variable immunodeficiency (CVID) is the most common symptomatic humoral deficiency in adults and is accompanied by digestive symptoms. It is associated with intestinal dysbiosis and half of the patients exert a clinical digestive disease, called enteropathy. Hepatic complications characterized by porto-sinusoidal vascular disease are observed in 10% of the CVID patients. This complication is associated with a high morbi-mortality. In our center experience and in the literature, clinical occurrence of enteropathy and hepatic disease are highly correlated. Considering (i) the anatomical link between the intestinal tractus and the portal circulation, (ii) the clinical correlation between enteropathy and the liver disease and (iii) the established relation between gut microbiota and alcoholic cirrhosis, we speculate that patients whom develop portosinusoidal complications exert a peculiar intestinal dysbiosis. This study could contribute to a better understanding of the hepatic disease development, hence allowing us to suggest novel therapies based on gut microbiota modification.
Interventions
BIOLOGICALStool sample
Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Patients with a common variable immunodeficiency according to immune deficiencies classification associated with : * enteropathy and porto-sinusoidal vascular disease * enteropathy without porto-sinuoidal vascular disease * Subject with health insurance (AME excepted) * Verbal agreement to participate at the study
Exclusion criteria
\- Laxatives in the month preceding stool sample
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of a dysbiosis | Day 7 | Evaluate the occurrence of dysbiosis and characterize gut microbiota (function and composition) by genomic (16S) and metabolomic (short chain fatty acids, bile acids, tryptophan metabolites) analyses from stool samples of patients with a common variable immunodeficiency with only enteropathy compared to patients with common variable immunodeficiency with enteropathy and porto-sinusoidal vascular disease |
| Characterization of gut microbiota | Day 7 | Evaluate the occurrence of dysbiosis and characterize gut microbiota (function and composition) by genomic (16S) and metabolomic (short chain fatty acids, bile acids, tryptophan metabolites) analyses from stool samples of patients with a common variable immunodeficiency with only enteropathy compared to patients with common variable immunodeficiency with enteropathy and porto-sinusoidal vascular disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fecal calprotectin measurement | Day 7 | Evaluate the contribution of fecal calprotectin measurement at diagnosis |
Countries
France
Contacts
Primary ContactJehane FADLALLAH, MD, PhD
Outcome results
None listed